Back to Search Start Over

MSH3 : a confirmed predisposing gene for adenomatous polyposis.

Authors :
Villy MC
Masliah-Planchon J
Schnitzler A
Delhomelle H
Buecher B
Filser M
Merchadou K
Golmard L
Melaabi S
Vacher S
Blanluet M
Suybeng V
Corsini C
Dhooge M
Hamzaoui N
Farelly S
Ait Omar A
Benamouzig R
Caumette V
Bahuau M
Cucherousset J
Allory Y
Stoppa-Lyonnet D
Bieche I
Colas C
Source :
Journal of medical genetics [J Med Genet] 2023 Nov 27; Vol. 60 (12), pp. 1198-1205. Date of Electronic Publication: 2023 Nov 27.
Publication Year :
2023

Abstract

Background: The MSH3 gene is part of the DNA mismatch repair system, but has never been shown to be involved in Lynch syndrome. A first report of four patients from two families, bearing biallelic MSH3 germline variants, with a phenotype of attenuated colorectal adenomatous polyposis raised the question of its involvement in hereditary cancer predisposition. The patients' tumours exhibited elevated microsatellite alterations at selected tetranucleotide repeats (EMAST), a hallmark of MSH3 deficiency.<br />Methods: We report five new unrelated patients with MSH3 -associated polyposis. We describe their personal and familial history and study the EMAST phenotype in various normal and tumour samples, which are relevant findings based on the rarity of this polyposis subtype so far.<br />Results: All patients had attenuated colorectal adenomatous polyposis, with duodenal polyposis in two cases. Both women had breast carcinomas. EMAST phenotype was present at various levels in different samples of the five patients, confirming the MSH3 deficiency, with a gradient of instability in polyps depending on their degree of dysplasia. The negative EMAST phenotype ruled out the diagnosis of germline MSH3 deficiency for two patients: one homozygous for a benign variant and one with a monoallelic large deletion.<br />Conclusion: This report lends further credence to biallelic MSH3 germline pathogenic variants being involved in colorectal and duodenal adenomatous polyposis. Large-scale studies may help clarify the tumour spectrum and associated risks. Ascertainment of EMAST may help with the interpretation of variants of unknown significance. We recommend adding MSH3 to dedicated diagnostic gene panels.<br />Competing Interests: Competing interests: None declared.<br /> (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.)

Details

Language :
English
ISSN :
1468-6244
Volume :
60
Issue :
12
Database :
MEDLINE
Journal :
Journal of medical genetics
Publication Type :
Academic Journal
Accession number :
37402566
Full Text :
https://doi.org/10.1136/jmg-2023-109341